Table 1. Demographic and clinical characteristics of re-treatment TB patients, defaulters (cases, N = 1,141) and non-defaulters (controls, N = 1,189), and bivariate risk factors for default, India 2006.
| Characteristic | Sub-category | Defaulter n (%) | Non–Defaulter n (%) | Odds Ratio (95% confidence interval) | p-value |
| Sex | Male | 907 (79.5%) | 853 (71.7%) | 1.56 (1.28–1.89) | <0.01 |
| Female | 234 (20.5%) | 336 (28.3%) | Referent | ||
| Age group | <15 years | 7 (0.6%) | 17 (1.4%) | 0.44 (0.17–1.07) | 0.05 |
| 15–24 years | 131 (11.5%) | 166 (14.0%) | 0.85 (0.63–1.14) | 0.26 | |
| 25–34 years | 267 (23.4%) | 288 (24.2%) | Referent | ||
| 35–44 years | 321 (28.1%) | 291 (24.5%) | 1.19 (0.94–1.51) | 0.13 | |
| 45–54 years | 219 (19.2%) | 242 (20.4%) | 0.98 (0.76–1.26) | 0.84 | |
| 55–64 years | 150 (13.1%) | 116 (9.8%) | 1.39 (1.03–1.89) | 0.26 | |
| >65 years | 46 (4.0%) | 69 (5.8%) | 0.72 (0.47–1.10) | 0.11 | |
| Classification | Pulmonary, Smear positive | 906(79.4%) | 914(76.8%) | Referent | |
| Pulmonary, Smear negative | 201(17.6%) | 221(18.6%) | 0.92 (0.74–1.14) | 0.42 | |
| Pulmonary, Smear unknown | 9(0.7%) | 14(1.2%) | 0.65 (0.26–1.6) | 0.31 | |
| Extra-pulmonary | 25 (2.2%) | 40 (3.4%) | 0.63 (0.37–1.08) | 0.07 | |
| Type of TB | Relapse | 376 (33.0%) | 450 (37.8%) | Referent | |
| Failure | 102 (8.9%) | 105 (8.8%) | 1.16 (0.85–1.60) | 0.33 | |
| Treatment after default | 429 (37.6%) | 364 (30.6%) | 1.41 (1.15–1.72) | <0.01 | |
| Others | 234 (20.5%) | 270 (22.7%) | 1.04 (0.83–1.30) | 0.74 | |
| Source of previous Treatment | RNTCP | 451 (39.5%) | 533 (44.8%) | Referent | |
| Non-RNTCP | 358 (31.4%) | 323 (27.2%) | 1.31 (1.07–1.60) | <0.01 | |
| Data missing | 332 (29.1%) | 333 (28.0%) | 1.18 (0.96–1.44) | 0.10 | |
| Nature of DOT provider | Public health facility | 829 (72.7%) | 786 (66.1%) | Referent | |
| Community provider | 155 (13.6%) | 159 (13.4%) | 0.92 (0.72–1.19) | 0.52 | |
| Medical college | 29 (2.5%) | 62 (5.2%) | 0.44 (0.28–0.71) | <0.01 | |
| Private provider | 90 (7.9%) | 130 (10.9%) | 0.66 (0.49–0.88) | <0.01 | |
| Non-governmental organization | 34 (3.0%) | 49 (4.1%) | 0.66 (0.41–1.05) | 0.06 | |
| Data missing | 4 (.4%) | 3 (.3%) | 1.26 (0.24–7.11) | 0.75 | |
| Missed doses during intensive phase of treatment* | 1 or more | 453 (39.7%) | 337 (28.3%) | 1.66 (1.39–1.99) | <0.01 |
| 2 or more | 379 (33.2%) | 270 (22.7%) | 1.69 (1.40–2.04) | <0.01 | |
| 3 or more | 322 (28.2%) | 224 (18.8%) | 1.68 (1.37–2.05) | <0.01 | |
| 4 or more | 281 (24.6%) | 178 (14.9%) | 1.86 (1.50–2.30) | <0.01 | |
| 5 or more | 249 (21.8%) | 150 (12.6%) | 1.93 (1.54–2.43) | <0.01 | |
| 6 or more | 216 (18.9% | 130 (10.9%) | 1.90 (1.49–2.42) | <0.01 | |
| 10 or more | 126 (11%) | 72 (6%) | 1.93 (1.41–2.63) | <0.01 | |
| Adverse reaction | Documented | 119 (10.4%) | 5 (0.4%) | 27.6 (10.8–76.7) | <0.01 |
| Not documented | 1022 (89.6%) | 1184 (99.6%) | Referent |
*Prior to the last dose documented. Sub-categories are mutually exclusive. Referent group for each comparison are those cases and controls with fewer missed doses than the number evaluated.